Artera Announces Three Presentations at ASCO 2024 That Demonstrate the Reliability and Depth of its AI Cancer Platform
The significant scalability of Artera’s groundbreaking multimodal AI platform is showcased with abstracts in advanced stages [...]
New Data Validating the First AI-Based Biomarker to Stratify Risk of Metastasis in Radical Prostatectomy Patients with Biochemical Recurrence
Results identified 40% of BCR patients who benefited from therapy intensification vs. 60% of patients who did not The data re [...]
ArteraAI and Movember Announce New Relationship
Harnessing AI to accelerate personalized cancer treatment SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimod [...]
ArteraAI Included in the 2024 NCCN Guidelines® for Prostate Cancer
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced [...]
ArteraAI Secures $20 Million in Funding to Further Personalize Cancer Therapy With Multimodal AI
The funding will support the international expansion and commercial growth of the company and its first-of-its-kind test SAN [...]
ArteraAI Receives Medicare Payment Rate for the ArteraAI Prostate Cancer Test
This is the first-of-its-kind AI-enabled test to provide predictive and prognostic results SAN FRANCISCO--(BUSINESS WIRE)--Ar [...]
ArteraAI Announces Research Agreement with CorePlus
The collaboration aims to further validate the ArteraAI Prostate Test in the Hispanic population SAN FRANCISCO--(BUSINESS WIR [...]
ArteraAI and GenesisCare Partner to Launch the First Australian-Based Clinical Trial
SAN FRANCISCO & SYDNEY--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predi [...]
ArteraAI and GenesisCare Partner to Provide Precision Cancer Therapy to Patients with Localized Prostate Cancer In Australia
Patients treated at GenesisCare clinics in Australia can work with clinicians to access AI-based decision making tools as par [...]